Respiratory papillomatosis is a rare and often severe disease, usually localized in the larynx. It may cause respiratory distress and even life-threatening obstruction of the airways. Treatment is generally based on the evaporation of the lesions with a CO2 laser, but microsurgery, cytotoxic and/or cytostatic drugs, interferons, and vaccines are also used. Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] (HPMPC) was shown to suppress the growth of tumors induced by rabbit papillomavirus as well as human papillomavirus (HPV). The efficacy of cidofovir was assessed in 17 patients with severe respiratory papillomatosis. Cidofovir at a concentration of 2.5 mg/ml was injected directly in the different laryngeal papillomatous lesions during microlaryngoscopy under general anesthesia. Biopsies were taken before the treatment was started both for anatomopathology and viral typing. HPMPC kinetics in serum was monitored in three patients, the drug levels being determined by high-performance liquid chromatography. Complete disappearance of the papillomatosis was observed in 14 patients. Four patients relapsed and were successfully treated again with cidofovir. Of the three remaining patients, one progressed while under treatment with cidofovir, after an initial marked response. One patient had a partial remission and remained stable for more than 1 year after the last injection. He had a very aggressive and extensive disease originally. Finally, one patient was lost to follow-up after four injections. Intratumoral injections of cidofovir for the treatment of severe laryngeal papillomatosis is a powerful new therapeutic approach for this disease. Treatment was well tolerated, and no significant side effects were noted.
Nucleotide Conformations: Rules and Exceptions.- Nuclear Magnetic Resonance Studies of Nucleoside Conformational Properties.- Methods of Nucleoside Synthesis.- Chemical Transformations of the Sugar Moiety of Nucleosides.- Chemistry of Naturally Occurring Pyrimidine Nucleosides and Analogues.- Chemistry of the Heterocyclic Moiety of Purine Nucleosides and Some Closely Related Analogues.- The Mechanisms of Inhibition of Cellular and Viral Multiplication by Aranucleosides and Aranucleotides.- Uptake and Metabolism of Purine Nucleosides and Purine Nucleoside Analogues by Cells.- Basis for the Selective Antiviral and Antitumour Activity of Pyrimidine Nucleoside Analogues.- Development of Antiherpes Virus Agents on the Basis of Virus Induced Enzymes.- Test Systems for Evaluating the Antiviral Activity of Nucleoside Analogues.- Test Systems for Evaluating the Antitumour Activity of Nucleoside Analogues.- Success of Antiviral Therapy Involves Cooperative Immune Responses.- The Clinical Uses of Nucleoside Analogues in Malignant Disease.- Industrial Development of New Drugs.- Participants.
The simian immunodeficiency virus (SIV) mnd(GB-1) strain, isolated from a mandrill, replicates in a human T cell line, CEM cells, and is inhibited by the CXC-chemokines, stromal cell-derived factor 1alpha and 1beta (SDF-1alpha/SDF-1beta), the natural ligands for CXCR4. The IC50 was around 70-80 ng/ml, which corresponds to the IC50 of SDF-1alpha/SDF-1beta for T-tropic human immunodeficiency virus type 1 (HIV-1) and HIV-2. The specific anti-CXCR4 MAb 12G5 inhibited replication of SIVmnd at an IC50 of 1 microg/ml. Also, the IC50 of 8 ng/ml for SIVmnd of the bicyclam AMD3100, a specific CXCR4 antagonist, is comparable with its IC50 for T-tropic HIV-1 and HIV-2 strains. Two other SIV strains, SIVagm3 and SIVmac251, were insensitive to SDF-1alpha/SDF-1beta, anti-CXCR4 MAb and AMD3100. SIVmnd replicates only in HOS.CD4 cells expressing CXCR4 and not in HOS.CD4 transfectants expressing CCR1, CCR2b, CCR3, CCR4 or CCR5. This is, to our knowledge, the first SIV strain found to use CXCR4 and not CCR5 as a main coreceptor for entering human cells.
No abstract is provided for this article.
No abstract is provided for this article.
